Mumbai, Washington DC, July 24, 2023: Lupin Digital Health, India’s first evidence-based cardiology digital therapeutics (DTx) platform and the American College of Cardiology (ACC), the global scientific leader in the practice of Cardiology, today announced a first-of-its-kind collaboration to deliver in-home cardiovascular care with Digital Therapeutics (DTx) in India. This collaboration aims to accelerate the application and adoption of DTx in Cardiology in India. Lupin Digital Health’s DTx platform, Lyfe, also aims to give patients and their healthcare providers tools to manage heart diseases at home and help to ensure patients stay healthy after hospital discharge and reduce rehospitalization.

India is grappling with a staggering burden of cardiovascular disease, predicted to have the highest number of cardiac deaths globally by 2030. As per the Indian Heart Association, heart diseases disproportionately affect Indians at a younger age, often without warning. Studies highlight that Indians suffer from heart ailments at least a decade earlier than their Western counterparts, underscoring the urgent need for preventive and comprehensive care.

This collaboration signifies a monumental leap in transforming cardiac care in India. Lupin Digital Health becomes the first Digital Therapeutics player in India to exclusively collaborate with ACC and provide comprehensive heart care. As part of this collaboration, Lupin Digital Health will leverage ACC’s CardioSmart platform, guidelines, and workbooks to guide healthcare professionals and caregivers. These tools will be accessible to doctors, patients, and caregivers through Lupin Digital Health’s Lyfe app and website, lyfe.in.

“This collaboration with Lupin Digital Health reflects our commitment to advancing equitable cardiovascular care globally and demonstrates how innovative collaborations can deliver transformative outcomes for patients in India,” stated ACC Chief Innovation Officer Ami B. Bhatt, MD, FACC.

“India’s vast talent pool and widespread adoption of smartphone-based technology present immense potential for leveraging Digital Therapeutics. Our focus is on delivering practical solutions that empower doctors to provide superior patient care. Through our collaboration with ACC, we aim to revolutionize the management of heart disease in India, enabling healthcare professionals and caregivers to provide effective care to patients outside of hospitals,” stated Rajeev Sibal, President – India Region Formulations, Lupin Limited.

Emphasizing the patient-centric approach of the collaboration, Sidharth Srinivasan, CEO of Lupin Digital Health, said, “The mounting burden of cardiovascular disease in India, affecting even the younger generation, makes this collaboration an urgent imperative. Lupin Digital Health’s unique value proposition lies in providing patients with the convenience of monitoring and rehabilitation, all from the comfort of their homes, while receiving comprehensive care from their treating cardiologists. This collaboration marks a significant milestone in the advancement of Digital Therapeutics in the field of cardiology in India.”

To promote the adoption of advanced digital solutions in Cardiology, ACC will provide certificates to cardiologists, recognizing their dedication to innovation and patient-centric healthcare. This collaboration plays a pivotal part in ensuring optimal care and driving improved outcomes within the comfort of patients’ homes.

About American College of Cardiology
The American College of Cardiology (ACC) is the global leader in transforming cardiovascular care and improving heart health for all. As the preeminent source of professional medical education for the entire cardiovascular care team since 1949, ACC credentials cardiovascular professionals in over 140 countries who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. Through its world-renowned family of JACC Journals, NCDR registries, ACC Accreditation Services, global network of Member Sections, CardioSmart patient resources and more, the College is committed to ensuring a world where science, knowledge and innovation optimize patient care and outcomes. Learn more at www.ACC.org or follow @ACCinTouch.

About Lupin Digital Health
Lupin Digital Health, a fully owned subsidiary of Lupin Limited, a leading global pharmaceutical company, is dedicated to developing cutting-edge digital health solutions that address unmet patient needs. Their flagship product, Lyfe, is a revolutionary digital therapeutics solution that harnesses the power of artificial intelligence (AI) and machine learning (ML) to deliver personalized and immersive patient experiences. Lyfe aims to tackle the critical challenge of effectively managing chronic diseases, thereby reducing the risks and expenses associated with hospitalization. By offering timely guidance on various health parameters, Lyfe empowers individuals to take charge of their well-being. With its seamless integration of health monitoring devices, widespread technological accessibility, and the expertise of renowned cardiologists, Lyfe provides a comprehensive cardiac care solution that enables individuals to regain control over their health and reshape the future of patient care.
Please visit https://lyfe.in/ for more information.

Follow us on LinkedIn: https://www.linkedin.com/company/lupin-digital-health/

About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.
Follow us on:
Twitter: https://twitter.com/LupinGlobal/
LinkedIn: https://www.linkedin.com/company/lupin
Facebook: http://www.facebook.com/LupinWorld/

For further information or queries, please contact –

Priyanka Chavda
Manager – Corporate Communications
Email: priyankachavda@lupin.com